Pharma
Strides Shasun receives USFDA nod to market nausea drug in US
Strides Shasun receives USFDA nod to market nausea drug in US
![]()
By eHealth Network - 03 July 2017
Bengaluru-based Indian pharmaceutical major Strides Shasun has announced that the company has received approval from US Food and Drug Administration (USFDA) to market Promethazine Hydrochloride tablets USP (12.5 mg, 25 mg, and 50 mg), which is used to prevent nausea and vomiting related to certain conditions.
The product will be manufactured at Strides Shasun’s Jigani plant located in Anekal taluka of the Bengaluru metropolitan area. The market for Promethazine Hydrochloride tablets in the US is estimated to be around $17 million, according to data provided by IMS Health, which provides information, services and technology for the healthcare industry.
Strides Shasun Ltd came into existence in 2014 after a merger of Shasun Pharmaceuticals with Strides Arcolab. The company has eight manufacturing units spread across three continents. Strides Shasun has three research and development centres in India with global filing capabilities.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
